Zilli, ThomasThomasZilliSiva, ShankarShankarSivaBrabrand, SigmundSigmundBrabrandDirix, PietPietDirixLiefhooghe, NickNickLiefhoogheOtte, François-XavierFrançois-XavierOtteGomez-Iturriaga, AlfonsoAlfonsoGomez-IturriagaEveraerts, WouterWouterEveraertsShelan, MohamedMohamedShelanConde-Moreno, AntonioAntonioConde-MorenoCampos, Fernando LópezFernando LópezCamposPapachristofilou, AlexandrosAlexandrosPapachristofilouGuckenberger, MatthiasMatthiasGuckenbergerScorsetti, MartaMartaScorsettiZapatero, AlmudenaAlmudenaZapateroIturre, Ana-Elena VillafrancaAna-Elena VillafrancaIturreEito, ClaraClaraEitoCouñago, FelipeFelipeCouñagoMuto, PaoloPaoloMutoDuthoy, WimWimDuthoyMach, NicolasNicolasMachFonteyne, ValérieValérieFonteyneMoon, DanielDanielMoonThon, KristianKristianThonMercier, CaroleCaroleMercierAchard, VéraneVéraneAchardStellamans, KarinKarinStellamansGoetghebeur, ElsElsGoetghebeurReynders, DriesDriesReyndersOst, PietPietOst2026-02-042026-02-042026-01-20https://boris-portal.unibe.ch/handle/20.500.12422/230342For prostate cancer patients with metachronous nodal oligorecurrences detected by positron emission tomography, the randomized phase 2 PEACE V-STORM trial (NCT03569241) demonstrated that, compared with metastasis-directed therapy (MDT), elective nodal pelvic radiotherapy (ENRT) in combination with 6 mo of androgen deprivation therapy (ADT) improved locoregional disease control and metastasis-free survival. In the 190 evaluable patients (MDT: 97 and ENRT: 93) of the 196 randomized in the study, health-related quality of life (HRQoL) was assessed by European Organization for Research and Treatment of Cancer QLQ-C-30 and QLQ-PR-25 questionnaires over a 4-yr period as a part of a statistically defined quality of life analysis. During a median follow-up of 50 mo (interquartile range 42-58), QLQ-C30 scores showed no significant differences between MDT and ENRT, except for worse physical functioning at month 24 in the ENRT group (mean decline -7.7 vs -1.3) and worse emotional functioning at month 12 in the MDT group (mean decline 5.8 vs -0.4, p = 0.034). No significant differences in QLQ-PR25 scores were observed, except slightly better bowel symptoms at 18 mo for ENRT, but with no difference before or after. The decline in sexual activity and increase in ADT-related symptoms during the first 6 mo were comparable between arms, returning to baseline by month 12. Consistent with physician-reported treatment-related adverse events, HRQoL analyses show no significant differences between ENRT and MDT.en600 - Technology::610 - Medicine & healtharticle10.48620/944004156555210.1016/j.euo.2026.01.001